Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults

Vaccine

Volumn 29, Issue 32, 2011, Pages 5145-5152

  Turley, Christine B ^a   Rupp, Richard E ^a   Johnson, Casey ^c   Taylor, David N ^b   Wolfson, Julie ^d   Tussey, Lynda ^b   Kavita, Uma ^b   Stanberry, Lawrence ^a   Shaw, Alan ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b VaxInnate Corporation   (United States)

^c Johnson County Clin Trials   (United States)

^d Veristat Inc   (United States)

Author keywords

Clinical trials; First time in human; Influenza; Universal vaccine

Indexed keywords

BACTERIUM ANTIBODY; C REACTIVE PROTEIN; FLAGELLIN; FLAGELLIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MATRIX PROTEIN; MATRIX PROTEIN 2; PLACEBO; RECOMBINANT MATRIX PROTEIN 2 ECTODOMAIN FLAGELLIN INFLUENZA VACCINE; UNCLASSIFIED DRUG; VAX 102; VIRUS ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; C REACTIVE PROTEIN BLOOD LEVEL; CHILL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SWEATING; VACCINE PRODUCTION; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES; C-REACTIVE PROTEIN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLAGELLIN; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, SYNTHETIC;

EID: 79960308363     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.041     Document Type: Article

References (25)

1. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N Engl J Med 2010, 363:2036-2044.
2. CDC Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine-Marshfield, Wisconsin, 2007-08 influenza season. MMWR 2008, 57:393-398.
3. Skowronski D.M., Masaro C., Kwindt T.L., Mak A., Petric M., Li Y., et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007, 25:2842-2851.
4. Gerhard W., Mozdzanowska K., Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006, 12:569-574.
5. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
6. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-2772.
7. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
8. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990, 64:1375-1377.
9. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13:1399-1402.
10. Frace A.M., Klimov A.I., Rowe T., Black R.A., Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999, 17:2237-2244.
11. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
12. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
13. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londoño-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26:6503-6507.
14. Mozdzanowska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007, 4:118.
15. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25:763-775.
16. McDonald W.F., Huleatt J.W., Foellmer H.G., Hewitt D., Tang J., Desai P., et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 2007, 195:1607-1617.
17. Fu T.M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27:1440-1447.
18. Treanor J.J., Taylor D.N., Tussey L., Hay C., Nolan C., Fitzgerald T., et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010, 28:8268-8274.
19. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
20. Black S., Kushner I., Samols D. C-reactive protein. J Biol Chem 2004, 279:48487-48490.
21. Song L., Zhang Y., Yun N.E., Poussard A.L., Smith J.N., Smith J.K., et al. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009, 27:5875-5884.
22. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23:366-371.
23. Zharikova D., Mozdzanowska K., Feng J., Zhang M., Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005, 79:6644-6654.
24. Talbot H.K., Rock M.T., Johnson C., Tussey L., Kavita U., Shanker A., et al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 2010, 5:e14442.
25. Song L., Nakaar V., Kavita U., Price A., Huleatt J., Tang J., et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 2008, 3:e2257.